Beneve Secures U.S. Network Marketing / Direct Sales Exclusivity for BIOMEnd™ Butyrate Ingredient

Beneve LLC has obtained exclusive U.S. network marketing rights to BIOMEnd™, a patented l-lysine butyrate ingredient positioned within the expanding gut health category.

The agreement provides Beneve with exclusive access to the ingredient for direct selling distribution channels in the United States, reinforcing the company’s emphasis on clinically supported wellness formulations and branded ingredient partnerships.

BIOMEnd is a next-generation form of butyric acid delivery developed to support digestive and intestinal health at a foundational level. Butyric acid, a naturally occurring short-chain fatty acid produced within the gut microbiome, has become an increasing focus of nutritional science due to its significant role in maintaining intestinal barrier integrity, supporting both microbial balance and natural GLP-1, the company shared, as well as contributing to overall digestive wellness.*

The BIOMEnd ingredient utilizes l-lysine butyrate technology designed to improve oral delivery and utilization of butyric acid within dietary supplements. According to available clinical data, BIOMEnd has been shown to demonstrate five times greater oral bioavailability than tributyrin, and superior oral bioavailability to sodium butyrate, positioning it among the most advanced commercially available butyrate delivery systems currently entering the supplement market.*

A published study examining the ingredient’s bioavailability profile can be found through the Journal of Exercise and Nutrition.

Beneve incorporated BIOMEnd into its Gut Advantage (G3) formulation, a multi-component gut health product structured around prebiotic, probiotic, postbiotic, and supportive nutritional components. The formula combines BIOMEnd with inulin fiber, dairy-free yogurt culture probiotics, and colostrum (sourced from grass-fed cows), to create a superior multi-layered gut health system designed to support digestive balance and microbiome function.*

The integration of BIOMEnd into Gut Advantage (G3) reflects Beneve’s broader product development strategy, which emphasizes premium ingredient sourcing, branded clinical technologies, and formulations positioned around efficacy rather than commodity supplementation. The company has consistently structured its wellness portfolio around identifiable ingredient systems with supporting scientific rationale and differentiated sourcing relationships.

The exclusivity arrangement also reflects strategic alignment between Beneve and Nutrashure, the ingredient innovation company behind BIOMEnd. That positioning aligns closely with Beneve’s broader organizational emphasis on physical, mental, and financial health through its “People Doing Good Together” operating philosophy. Rather than approaching supplementation through trend-driven product expansion, Beneve has increasingly emphasized integrated wellness systems supported by ingredient partnerships and long-term category positioning, the company shared.

As consumer awareness surrounding microbiome health and digestive wellness continues to expand, butyric acid has emerged as an increasingly studied category within nutritional supplementation. Through its exclusive U.S. network marketing rights to BIOMEnd, Beneve stated that it is positioning itself beyond the growing field of mere generic white-labeled gut health products, by aligning with a formulation strategy centered on proprietary butyrate delivery technology, ingredient specificity, and clinically supported design. According to company leadership, rather than competing primarily through branding or commodity replication, its positioning reflects a focus on differentiated product architecture within a category that has become increasingly crowded with standardized formulations.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always check with your physician before starting a new dietary supplement program.